SCHEMBL7534833

SCHEMBL7534833

COc1ccc(Cl)cc1NS(=O)(=O)c1cc2oc(=O)n(C)c2cc1C

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
USP2 O75604 1/20 0.53
MAPT P10636 2/20 0.51
TP53 P04637 4/20 0.50
TSHR P16473 2/20 0.49
IDH1 O75874 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 2/20 0.47
NPC1 O15118 1/20 0.47
BRPF1 P55201 3/20 0.47
BRD1 O95696 2/20 0.47
TRIM24 O15164 1/20 0.47
WDR5 P61964 1/20 0.47
BRD4 O60885 3/20 0.46
BRPF3 Q9ULD4 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7533432 0.96 ALDH1A1 (0.53) ALDH1A1USP2MAPTTP53TSHR
SCHEMBL7537050 0.89 TP53 (0.53) ALDH1A1USP2MAPTTP53TSHR
SCHEMBL7501360 0.88 BRD4 (0.57) ALDH1A1USP2TP53TSHRMEN1
SCHEMBL7537329 0.87 ALDH1A1 (0.59) ALDH1A1USP2MAPTTP53TSHR
SCHEMBL7499285 0.87 BRD4 (0.61) ALDH1A1USP2TP53TSHRMEN1
SCHEMBL7543535 0.84 TP53 (0.59) TP53IDH1LMNABRPF1BRD4
SCHEMBL7536317 0.83 TP53 (0.71) ALDH1A1USP2TP53TSHRMEN1
SCHEMBL7501770 0.83 TP53 (0.55) ALDH1A1USP2TP53TSHRMEN1
SCHEMBL7542434 0.83 ALDH1A1 (0.59) ALDH1A1USP2MAPTTP53TSHR
SCHEMBL7507552 0.82 TSHR (0.59) ALDH1A1USP2TP53TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS INC (US) 2017-01-12 US disclosed
EP-2427441-B1 PKM2 ACTIVATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS INC (US) 2016-12-14 EP disclosed
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-8501953-B2 PKM2 modulators for use in the treatment of cancer AGIOS PHARMACEUTICALS, INC (US) 2013-08-06 US disclosed
WO-2013056153-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE KUNG CHARLES (US) 2013-04-18 WO disclosed
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed
WO-2010129596-A1 PMK2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER PDK2, PDK1, PDK3 ALDH1A1 1326/4885USP2 3697/4885MAPT 3769/4885
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 ALDH1A1 1390/4885USP2 2751/4885MAPT 2681/4885
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 ALDH1A1 1390/4885USP2 2751/4885MAPT 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.